Humana (NYSE:HUM) Receives New Coverage from Analysts at Piper Sandler

Piper Sandler started coverage on shares of Humana (NYSE:HUM) in a research report report published on Wednesday morning, MarketBeat.com reports. The firm issued an overweight rating and a $392.00 target price on the insurance provider’s stock.

HUM has been the topic of a number of other reports. Baird R W upgraded shares of Humana to a hold rating in a report on Thursday, May 30th. Morgan Stanley initiated coverage on shares of Humana in a research note on Monday. They issued an equal weight rating and a $374.00 target price for the company. Cantor Fitzgerald reissued a neutral rating and issued a $360.00 target price on shares of Humana in a research note on Wednesday, June 12th. Wells Fargo & Company decreased their target price on shares of Humana from $413.00 to $350.00 and set an overweight rating for the company in a research note on Monday, April 8th. Finally, UBS Group decreased their target price on shares of Humana from $334.00 to $326.00 and set a neutral rating for the company in a research note on Thursday, April 25th. Fourteen analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of Hold and a consensus target price of $409.55.

Humana Price Performance

NYSE HUM opened at $361.09 on Wednesday. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. Humana has a 12-month low of $298.61 and a 12-month high of $530.54. The company has a market capitalization of $43.51 billion, a PE ratio of 22.48, a price-to-earnings-growth ratio of 2.08 and a beta of 0.53. The firm’s 50 day moving average is $341.39 and its 200-day moving average is $354.08.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company had revenue of $29.61 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same period last year, the company earned $9.38 earnings per share. The firm’s revenue was up 10.7% compared to the same quarter last year. Equities research analysts anticipate that Humana will post 16.12 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a $0.885 dividend. The ex-dividend date is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.98%. Humana’s payout ratio is presently 22.04%.

Institutional Investors Weigh In On Humana

A number of institutional investors have recently modified their holdings of HUM. Norges Bank acquired a new position in Humana in the fourth quarter valued at about $676,800,000. Sanders Capital LLC acquired a new position in Humana in the fourth quarter valued at about $489,300,000. Ontario Teachers Pension Plan Board raised its stake in Humana by 11,647.2% in the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock valued at $367,342,000 after purchasing an additional 1,050,459 shares in the last quarter. Putnam Investments LLC raised its stake in Humana by 550.3% in the fourth quarter. Putnam Investments LLC now owns 875,489 shares of the insurance provider’s stock valued at $400,808,000 after purchasing an additional 740,858 shares in the last quarter. Finally, Steadfast Capital Management LP acquired a new position in Humana in the first quarter valued at about $158,813,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.